Global Hemoglobinopathies Market Set for Rapid Growth, to reach Value around USD 11,409.84 Million by 2025

Zion Market Research has published a new report titled “Hemoglobinopathies Market by Indication (sickle cell disease, alpha thalassemia, beta thalassemia and others), Therapy (blood transfusion, iron chelation therapy, bone marrow transplant, and others), Diagnosis (blood testing, genetic testing, pre-implantation genetic diagnosis (PGD) and others), End user (Hospitals, Diagnostic laboratories, Clinics, Other End-user): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025”. According to the report, global demand for Hemoglobinopathies market was valued at approximately USD 5,790.0 million in 2018, and is expected to generate revenue of around USD 11,409.84 million by end of 2025, growing at a CAGR of around 10.25% between 2019 and 2025.

Browse the full “Hemoglobinopathies Market: by Indication (sickle cell disease, alpha thalassemia, beta thalassemia and others), Therapy (blood transfusion, iron chelation therapy, bone marrow transplant, and others), Diagnosis (blood testing, genetic testing, pre-implantation genetic diagnosis (PGD) and others), End user (Hospitals, Diagnostic laboratories, Clinics, Other End-user) – Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025” Report at https://www.zionmarketresearch.com/report/hemoglobinopathies-market

Hemoglobinopathies are created due to gene defects and anemia. Default hemoglobin formation is found in three circumstances such as structural defects of the hemoglobin molecule, decreased development of one of the two subunits of the hemoglobin molecule, and irregular interactions of otherwise healthy subunits. Serious or moderate diseases can occur. Genetic diagnosis, genetic and blood examination, alkaline and acid gel electrophoresis, hemoglobin electrophoresis, genetic prenatal testing, and ion exchange chromatography HbA2 are the most common tools / tests for hemoglobinopathy diagnosis and thalassemia disorders.

Increased R&D efforts to develop new treatments are expected to lead to market growth. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports SCD research projects to develop new ways to detect and treat the disease and improve the outcomes of patients. New procedures are being developed using advances in gene-editing technology to alter or remove the faulty SCD gene and transfer the restored gene back to the patients. Increasing funding for SCD prevention and treatment through legislation such as the Sickle Cell Disease Study, Monitoring, Prevention and Treatment Act, 2018 is also likely to contribute to enhanced situation management.

The market for Hemoglobinopathies is segmented based on indication, therapy, diagnosis, end-user and region. Based on Indication, the market is segmented into sickle cell disease, alpha thalassemia, beta thalassemia and others. SCD was the biggest selling group in 2018. The segment is also projected to grow over the forecast period at a healthy CAGR due to increased efforts to improve patient knowledge of the disorder and subsequent improvements in diagnosis and treatment. Based on therapy, the market is segmented into Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant and Others. The largest market share in blood transfusion therapy was retained in 2018. Increasing the number of blood donations in government initiatives is a high impact on the hemoglobinopathy market making factor.

Based on diagnosis, the market is segmented into     blood testing, genetic testing, pre-implantation genetic diagnosis (PGD) and others. Blood testing contributed to the 2018 section of revenue-related care. The fact that blood testing is commonly used as the first-line screening process is a key contributor to its major market share. Genetic testing for SCD diagnosis is projected to be the fastest growing segment over the forecast period due to its effectiveness in accurate diagnosis and monitoring. Based on end-user, the market is segmented into hospitals, diagnostic laboratories, clinics and other end-user. In 2018, the market dominated by hospitals.

Regional segmentation comprises the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. In 2018, North America led the overall revenue market because of rising R&D spending by key players, better reimbursement scenario, and the availability of high-quality healthcare services.

Some of the players included in Hemoglobinopathies market are Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation, Emmaus Life Sciences Inc., Gamida Cell, Global Blood Therapeutics, Prolong Pharmaceuticals, Sangamo, Therapeutics Inc., Sanofi amongst others.

The report segments global Hemoglobinopathies market as follows:

Global Hemoglobinopathies Market: Indication Segment Analysis

• Sickle cell disease
• Alpha Thalassemia
• Beta Thalassemia
• Others

Global Hemoglobinopathies Market: Therapy Segment Analysis

• Blood Transfusion
• Iron Chelation Therapy
• Bone Marrow Transplant
• Others

Global Hemoglobinopathies Market: Diagnosis Segment Analysis

• Blood testing
• Genetic testing
• Pre-implantation Genetic Diagnosis (PGD)
• Other

Global Hemoglobinopathies Market: End-user Segment Analysis

• Hospitals
• Diagnostic laboratories
• Clinics
• Other End-user

Global Hemoglobinopathies Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com